Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $76,895.00 in Stock

by · The Cerbat Gem

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Francis Lo sold 4,394 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $17.50, for a total transaction of $76,895.00. Following the completion of the transaction, the insider directly owned 315,978 shares of the company’s stock, valued at approximately $5,529,615. The trade was a 1.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Francis Lo also recently made the following trade(s):

  • On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.57, for a total transaction of $1,773,267.30.

Adaptive Biotechnologies Stock Down 0.3%

Adaptive Biotechnologies stock traded down $0.05 during mid-day trading on Monday, reaching $16.65. 2,236,944 shares of the company’s stock were exchanged, compared to its average volume of 2,087,879. Adaptive Biotechnologies Corporation has a twelve month low of $5.91 and a twelve month high of $20.76. The company has a market cap of $2.54 billion, a P/E ratio of -30.83 and a beta of 2.20. The company has a fifty day moving average of $16.63 and a 200-day moving average of $13.93.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The business had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The company’s quarterly revenue was up 102.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. Equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of hedge funds have recently modified their holdings of the business. CIBC Bancorp USA Inc. purchased a new stake in Adaptive Biotechnologies in the 3rd quarter valued at $238,000. Harvest Investment Services LLC grew its position in Adaptive Biotechnologies by 104.7% during the 3rd quarter. Harvest Investment Services LLC now owns 344,512 shares of the company’s stock worth $5,154,000 after purchasing an additional 176,235 shares during the last quarter. Oberweis Asset Management Inc. increased its stake in Adaptive Biotechnologies by 23.3% in the third quarter. Oberweis Asset Management Inc. now owns 726,500 shares of the company’s stock valued at $10,868,000 after purchasing an additional 137,100 shares during the period. Castleark Management LLC acquired a new position in Adaptive Biotechnologies in the third quarter valued at $4,459,000. Finally, CANADA LIFE ASSURANCE Co raised its holdings in shares of Adaptive Biotechnologies by 17.6% in the third quarter. CANADA LIFE ASSURANCE Co now owns 30,469 shares of the company’s stock valued at $456,000 after buying an additional 4,552 shares during the last quarter. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on ADPT. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, October 8th. JPMorgan Chase & Co. upped their target price on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 target price on the stock. Guggenheim started coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 30th. They set a “buy” rating and a $20.00 price target for the company. Finally, BTIG Research raised their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.11.

View Our Latest Analysis on ADPT

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

See Also